Eli Lilly agreed to acquire Merida Biosciences in a deal valued at up to $2.875 billion, marking its 13th acquisition of 2026. The purchase gives Lilly a foothold in therapies aimed at selectively degrading pathogenic autoantibodies, an immunology approach designed to target drivers of autoimmune disease rather than broadly suppress immune function. Merida’s focus on rogue antibody biology aligns with the broader market push toward targeted protein-degradation modalities. The transaction expands Lilly’s immunology portfolio and may accelerate internal platform development around degraders for immune-mediated conditions. For investors, the deal underscores Lilly’s willingness to pay for differentiated immunology mechanisms while keeping pressure on competitors building their own targeted strategies in autoimmune and inflammatory disease.